Inactive Instrument

Highlights Regenicin, Inc. Other OTC

Equities

RGIN

US75887Q1022

Highlights

Unlock all the news: Be the first to know and act before the market!

Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-15	CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-13	CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	23-01-13	CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-12	CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-05-23	CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	22-02-14	CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	22-01-13	CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021	21-08-23	CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	21-05-17	CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	21-01-13	CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020	20-08-19	CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2020	20-05-20	CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2019	20-02-19	CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2019	20-01-14	CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2019	19-08-19	CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2019	19-05-20	CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2018	19-02-19	CI
Regenicin Inc. Signs Supplier Agreement with Pure Med Farma LLC to Provide Closed Herd Collagen for the Manufacturing of NovaDerm	16-11-17	CI
Regenicin Completes Pre-IND Meeting with Food and Drug Administration for its New Autologous Cultured Skin Substitute, NovaDerm	16-11-01	CI
U.S. Food and Drug Administration Grants Orphan-Drug Designation for Regenicin's NovaDerm® Cultured Skin Substitute	16-08-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Regenicin, Inc. Other OTC

Equities

RGIN

US75887Q1022

Highlights

Filters